97th DOG Annual Meeting 1999

P533

UVEITIS: EPIDEMIOLOGY AND REFERRAL PATTERN IN A TERTIARY EYE CARE CENTER

N. Torun, S. Priem*, A. Liekfeld, H. Baatz, C. Jaeckel


Purpose: To determine the frequency of uveitis patterns and associated diseases in a referral center.

Methods: The records of 254 patients referred between 6/1996 and 12/1998 to the outpatient clinic of the Departs. of Ophthalmology and Internal Medicine III, Charité were analysed. The current „International Uveitis Study Group" classification system was used for anatomic classification. All patients underwent a standard diagnostic protocol and, as indicated, additional diagnostic tests. Aqueous humor analysis was performed in 60 patients. Data were analysed regarding sex and age of patients at presentation and onset of uveitis, clinical characteristics and systemic diseases. Patients positive for human immunodeficiency virus infection were excluded.

Results: The male:female ratio was 1:1.25 with a mean age at disease onset of 34.9 years. In 49.2% of patients a specific diagnosis could be established. Posterior uveitis was the most frequent manifestation (42%) followed by anterior uveitis (32%), intermediate uveitis (18%) and panuveitis (8%). Infectious causes of intraocular inflammation were identified as toxoplasmosis (12%), Herpes simplex virus (4.8%), borreliosis (2.4%), VZV (2.4%), Candida (1.0%) and Cytomegalovirus (0.5%). Intraocular antibody production was particularly helpful to establish the diagnosis. 195 non-infectious entities included HLA-B27 associated spondylarthropathies (6.9%), juvenile rheumatoid arthritis (2.8%), sarcoidosis (3.3%) and Behçets disease (1.0%).

Conclusions: Infectious processes still remain a major cause of intraocular inflammation and are a significant risk for uncontrolled corticosteroid treatment. The predominance of posterior uveitis may indicate a shift to more sight threatening manifestations but may also be related to the referral character of our institution.

Departments of Ophthalmology and Internal Medicine III*, Charité, Humboldt University, Berlin. Supported by Charité Grant.


Back